Open AccessEffect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
Author(s) -
Martin Lambert,
Pedro Sánchez,
Paul Bergmans,
Srihari Gopal,
Maju Mathews,
Annette Wooller,
Katalin Pungor
Publication year - 2020
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s286654
Subject(s) - medicine , paliperidone palmitate , clinical endpoint , schizophrenia (object oriented programming) , clinical trial , pediatrics , psychiatry , antipsychotic
This pragmatic clinical study aimed to assess goal attainment among patients with schizophrenia treated with paliperidone palmitate 3-monthly (PP3M) and its relation to their level of disability, and whether patients achieved symptomatic remission at the study endpoint.